Donna L. Barnd

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Donna L. Barnd, Michael S. Lan, Richard S. Metzgar et al. · Proceedings of the National Academy of Sciences · 1989 · 454 citations · Full text

Life Sciences, Immunology, Oncology +17

Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Keith R. Jerome, Donna L. Barnd, Katharine M. Bendt et al. · PubMed · 1991 · 353 citations

Life Sciences, Immunology, Oncology +17

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2003 · 321 citations

Medicine, Immunology, Oncology +17

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2004 · 146 citations · Full text

Life Sciences, Immunology, Oncology +17

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients

Galina V. Yamshchikov, Donna L. Barnd, Shannon Eastham et al. · International Journal of Cancer · 2001 · 115 citations

Medicine, Immunology, Oncology +17